372 related articles for article (PubMed ID: 32321829)
1. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
[TBL] [Abstract][Full Text] [Related]
2. Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.
Loo SK; Yates ME; Yang S; Oesterreich S; Lee AV; Wang XS
Genes Chromosomes Cancer; 2022 May; 61(5):261-273. PubMed ID: 35106856
[TBL] [Abstract][Full Text] [Related]
3. ETV6 gene aberrations in non-haematological malignancies: A review highlighting ETV6 associated fusion genes in solid tumors.
Biswas A; Rajesh Y; Mitra P; Mandal M
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188389. PubMed ID: 32659251
[TBL] [Abstract][Full Text] [Related]
4. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
[TBL] [Abstract][Full Text] [Related]
5. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.
Guilmette J; Dias-Santagata D; Nosé V; Lennerz JK; Sadow PM
Hum Pathol; 2019 Jan; 83():50-58. PubMed ID: 30130630
[TBL] [Abstract][Full Text] [Related]
6. ETV6 Gene Rearrangements Characterize a Morphologically Distinct Subset of Sinonasal Low-grade Non-intestinal-type Adenocarcinoma: A Novel Translocation-associated Carcinoma Restricted to the Sinonasal Tract.
Andreasen S; Skálová A; Agaimy A; Bishop JA; Laco J; Leivo I; Franchi A; Larsen SR; Erentaite D; Ulhøi BP; von Buchwald C; Melchior LC; Michal M; Kiss K
Am J Surg Pathol; 2017 Nov; 41(11):1552-1560. PubMed ID: 28719468
[TBL] [Abstract][Full Text] [Related]
7. Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.
Lukes J; Potuckova E; Sramkova L; Stary J; Starkova J; Trka J; Votava F; Zuna J; Zaliova M
Genes Chromosomes Cancer; 2018 Sep; 57(9):471-477. PubMed ID: 29726059
[TBL] [Abstract][Full Text] [Related]
8. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement.
Majewska H; Skálová A; Stodulski D; Klimková A; Steiner P; Stankiewicz C; Biernat W
Virchows Arch; 2015 Mar; 466(3):245-54. PubMed ID: 25503077
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
10. RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors.
Motta M; Barresi S; Pizzi S; Bifano D; Lopez Marti J; Garrido-Pontnou M; Flex E; Bruselles A; Giovannoni I; Rotundo G; Fragale A; Tirelli V; Vallese S; Ciolfi A; Bisogno G; Alaggio R; Tartaglia M
J Pathol; 2024 Jun; 263(2):166-177. PubMed ID: 38629245
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.
Brenca M; Rossi S; Polano M; Gasparotto D; Zanatta L; Racanelli D; Valori L; Lamon S; Dei Tos AP; Maestro R
J Pathol; 2016 Mar; 238(4):543-9. PubMed ID: 26606880
[TBL] [Abstract][Full Text] [Related]
12. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
13. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
Li Y; Wang S; Wei X; Zhang S; Song Z; Chen X; Zhang J
Cancer Sci; 2019 Feb; 110(2):561-567. PubMed ID: 30467925
[TBL] [Abstract][Full Text] [Related]
14. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.
Shaver TM; Lehmann BD; Beeler JS; Li CI; Li Z; Jin H; Stricker TP; Shyr Y; Pietenpol JA
Cancer Res; 2016 Aug; 76(16):4850-60. PubMed ID: 27231203
[TBL] [Abstract][Full Text] [Related]
15. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing and molecular cytogenetic characterization of ETV6-LYN fusion due to chromosomes 1, 8 and 12 rearrangement in acute myeloid leukemia.
Ma ESK; Wan TSK; Au CH; Ho DN; Ma SY; Ng MHL; Chan TL
Cancer Genet; 2017 Dec; 218-219():15-19. PubMed ID: 29153093
[TBL] [Abstract][Full Text] [Related]
17. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract][Full Text] [Related]
18. Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements.
Jebastin JAS; Smith SC; Perry KD; Gupta NS; Alanee S; Carskadon S; Chitale DA; Palanisamy N; Williamson SR
Histopathology; 2018 Aug; 73(2):321-326. PubMed ID: 29617048
[TBL] [Abstract][Full Text] [Related]
19. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
20. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
